Key Points {#sec18}
==========

There are around 100,000 new stroke cases and over a million people living with its consequences each year in the UK.On average, new onset strokes cost £45 k in the first year & £25 k in subsequent years, totalling £26 billion per year (UK).Interventions for rehabilitation and reducing new and recurrent stroke could yield substantial benefits and savings.

Introduction {#sec1}
============

The global lifetime risk of stroke is approximately 25% from the age of 25 years \[[@ref1]\], making it the second largest cause of death worldwide and fourth in the UK. There are over 113,000 new strokes annually in the UK \[[@ref2]\], a quarter of which occur among the under 65 s \[[@ref3]\]. Many of the estimated 950,000 stroke survivors \[[@ref4]\] experience significant and long-term residual physical and psychological impacts, repeat strokes, transient ischaemic attacks and/or death within a year of stroke. \[[@ref3]\] Stroke prevention and treatment, and its morbidity and mortality impacts, carry economic consequences across society \[[@ref5],[@ref6]\]. Despite significant progress in prevention, treatment and rehabilitation, there is a great capacity for further improvements and thus reduced economic impacts. This is ever more important given pressures faced by both formal and unpaid care sectors.

Understanding the scale and range of consequences can help prioritize scarce resources. The annual societal cost of stroke in the UK has previously been estimated at £9 billion (2005 prices), with over half attributed to lost employment and unpaid ('informal') care \[[@ref5]\]. There is a need for updated estimates to ensure future service, and policy responses can be discussed in the context of timely and relevant data.

Methods {#sec2}
=======

We synthesized data from multiple sources to estimate annual mean cost per person and the aggregate UK cost of stroke affecting individuals aged ≥40 years. A societal perspective incorporated formal health and social care (hospitals, community care and care homes), unpaid care and lost productivity arising due to stroke-related morbidity and early mortality. Costs in the year following a first-stroke episode formed the basis for costs of incident (new) stroke, while annual costs in subsequent years represented costs of prevalent stroke (stroke survivors). Mean costs were further gauged by sex, age (40--64, 65--74, 75--84, ≥85 years), stroke type (ischaemic or haemorrhagic) and stroke severity (National Institutes of Health Strokes Score (NIHSS) 1--2 for no/mild stroke (NIHSS score of 0--4), 3 for moderate stroke (scores 5--15) and 4--5 for severe stroke (scores 16--42)). Reported costs are for the 2014/2015 cost year in Great British Pound Sterling (GBP, £).

Average cost of formal health and social care {#sec3}
---------------------------------------------

Estimates for National Health Service (NHS) and Personal Social Services (PSS) costs were obtained using a modified version of a cost-of-illness model \[7,8\] developed by the National Guideline Centre (NGC) and the Sentinel Stroke National Audit Programme (SSNAP) at the Royal College of Physicians (RCP) on behalf of NHS England. They used data from SSNAP (April 2013---March 2015; *n* = 111,846) and the South London Stroke Register (SLSR) to inform a discrete event simulation (DES) model, which represented the probability of progression and length of stay in various settings in the stroke pathway, conditional on patient characteristics. The pathway started with admission to a hospital acute stroke unit. Subsequent progression to other settings (stroke unit, early supported discharge, community rehabilitation), discharge (to care home or own home) or death was conditional on individual factors, such as age, sex and stroke severity. Upon discharge from hospital, the patient's journey continues through repeat strokes, care home admission or death. Stroke services included in the model are detailed by Xu *et al*. \[7,8\] and are summarized in [Figure 1](#f1){ref-type="fig"} and [Supplementary Appendix 1](#sup1){ref-type="supplementary-material"}.

![Pathways represented in the NGC model.](afz162f1){#f1}

We modified the NGC model to generate separate estimates for incident and prevalent stroke. Cross-sectional data collection points were changed from 1 and 5 years post-stroke to 1, 2, 3 and 4 years post-stroke. Costs incurred in the first 12 months were then attributed to incident stroke and average costs incurred in years 2, 3 and 4 were used as a proxy for prevalent stroke. Costs incurred in years 2, 3 and 4 post-stroke were adjusted for the proportion of patients alive at the start of the corresponding year to avoid underestimating the true cost of follow-up care of stroke survivors. Unit costs were also updated (see below).

Average cost of unpaid care {#sec4}
---------------------------

Costs of care provided by family and other unpaid carers were estimated using control arm data from two large UK-based randomized controlled stroke rehabilitation trials: TRACS \[[@ref9]\] and LoTS Care \[[@ref10]\]. Both provided self-reported data at 6 and 12 months post-recruitment on number of hours spent by all resident and non-resident unpaid carers on personal care and a range of other tasks such as preparing meals, gardening and help with managing finances. Neither trial sought to assess inputs specifically attributable to stroke due to the difficulties in doing so but did ask respondents to report assistance received due to illness/injury over and above any help they received normally. For stroke incidence costs, we used unpaid care hours over the full 12-month period from the TRACS trial; for stroke prevalence costs, we used unpaid care hours from only the last 6 months of follow-up from the LoTS Care trial to better reflect longer-term inputs (the trial recruited patients at hospital discharge, thus data collected at 12 months post-recruitment \[covering the previous 6 months\] relates at least partially to the period beyond 1 year post-stroke).

Since the requirement for a primary unpaid carer for inclusion in TRACS risked over-estimating unpaid care inputs for our purposes, we used the trial's participant inclusion flow chart \[[@ref11]\] to determine the proportion of patients screened but excluded for absence of a primary carer, and added the equivalent proportion of simulated participants into the model. Mean unpaid care costs for these additional patients were assumed as 25% of those for people with a primary carer.

Average cost of lost productivity {#sec5}
---------------------------------

LoTS Care trial data \[[@ref10]\] were also used for estimating lost productivity. We used data on changed employment status (e.g. moving from full- to part-time working, or not working) and mortality 6 months after stroke for stroke incidence costs and the equivalent figures at 12 months for stroke prevalence costs. Number of hours spent in full- (37.6 hours per week) and part-time (16.2 hours per week) work were assumed from national data \[[@ref12]\].

Unit costs {#sec6}
----------

Unit costs ([Supplementary Appendix 2](#sup1){ref-type="supplementary-material"}) for health and social care were derived from published UK sources for the 2014/2015 financial year \[[@ref13]\].

National aggregate costs and estimates of incidence and prevalence {#sec7}
------------------------------------------------------------------

To derive the aggregate cost of stroke in the UK, we multiplied estimated mean cost of incident and prevalent stroke by estimated absolute incidence and prevalence. These in turn were calculated by combining age-specific incidence and prevalence rates per 1,000 people reported in literature with mid-2016 age-specific population figures \[[@ref17]\] for adults aged **≥**40 years; this accounted for changes in the age structure of the UK population.

A focused review of UK studies identified three key studies each for stroke incidence \[[@ref2],[@ref18],[@ref19]\] and prevalence \[[@ref4],[@ref20],[@ref21]\]. We excluded three incidence studies for inclusion of transient ischaemic attack \[22,23\] and focused only on ischaemic stroke \[24\].

From included studies, we estimated stroke incidence in 2015 ranged from 113,400 to 119,100, with a potential range from 85,800 to 147,600 when using low and high estimates reported in individual studies (We later used these ranges in our sensitivity analyses---see below.) As a point estimate, we focused on the mid-point estimate of 117,600 \[[@ref19]\].

Similarly, we estimated stroke prevalence ranged from 950,000 to 1.3 million, or 797,000 to 1.4 million when accounting for reported ranges. In estimating ranges for stroke prevalence, we adjusted numbers from individual studies to represent the full population of interest e.g. Geddes *et al*. \[[@ref4]\] only sampled individuals aged **≥**55 years, so we used estimates from O'Mahony *et al*. \[[@ref21]\] to generate estimates for younger adults. As the mid-point estimate of 1,002,600 reported by Jagger *et al*. \[[@ref20]\] was from a simulation and based on old data (1991--1994), we instead used Geddes *et al*.'s \[[@ref4]\] figure (950,200; based on *n* = 18,827) for our point estimate.

Analysis of uncertainty {#sec8}
-----------------------

Estimates of mean cost produced by a DES model can be influenced by sampling variation across individuals within the model, particularly in subgroups containing small patient numbers (i.e. Monte Carlo error). To minimize individual-level uncertainty and obtain stable estimates of 95% confidence intervals (CI) for mean cost, input values were repeatedly sampled over a large number of iterations. Repeated testing and validation determined that 500 replications of the model output with 4,000 individuals per run were necessary to achieve stable values for the point estimate and standard error.

To determine the effect of uncertainty around individual parameters, we used one-way sensitivity analyses to vary values such as assumed length of stay in stroke units and transition probabilities ([Supplementary Appendix 3](#sup1){ref-type="supplementary-material"}).

Uncertainty in aggregate cost estimates was gauged by substituting lower and upper estimates of incidence and prevalence and by applying 95% CI for mean cost in each cost category derived from the NGC model.

Results {#sec9}
=======

Mean costs of stroke {#sec10}
--------------------

The mean annual cost per person from an NHS and PSS perspective in the first year post-stroke is £18,081 (95% CI 17,621--18,542) with £13,269 (95% CI 13,058--13,480) and £4,812 (95% CI 4,434--5,190) attributable to NHS and PSS, respectively ([Table 1](#TB1){ref-type="table"}). Annual NHS and PSS costs for subsequent years total £7,759 (95% CI 7,200--8,318), but a greater portion becomes attributable to PSS rather than NHS care (£5,544 versus £2,215).

###### 

Mean cost of incident and prevalent stroke

                                            NHS & PSS cost   Unpaid care & lost productivity cost   Total cost                             
  ----------------------------------------- ---------------- -------------------------------------- ------------ ---------------- -------- ----------------
  First year cost (incident stroke)                                                                                                        
  All patients                              18,081           17,621--18,542                         27,328       24,434--30,221   45,409   42,054--48,763
  Age (years)                                                                                                                              
  40--64                                    12,770           12,089--13,451                         33,191       26,567--39,815   45,961   38,656--53,266
  65--74                                    15,577           14,742--16,412                         25,800       21,351--30,248   41,377   36,093--46,660
  75--84                                    20,011           19,201--20,820                         27,487       22,924--32,050   47,497   42,124--52,870
  ≥85                                       22,961           21,892--24,029                         18,234       11,274--25,194   41,195   33,166--49,223
  Sex                                                                                                                                      
  Male                                      17,338           16,725--17,950                         29,062       24,914--33,210   46,400   41,639--51,160
  Female                                    18,824           18,198--19,451                         25,090       21,196--28,984   43,914   39,394--48,435
  Stroke type                                                                                                                              
  Ischaemic                                 17,063           16,432--17,694                         27,167       23,928--30,407   44,231   40,360--48,101
  Haemorrhage                               19,099           18,455--19,743                         27,599       22,124--33,074   46,698   40,578--52,817
  Subsequent year cost (prevalent stroke)                                                                                                  
  All patients                              7,759            7,200--8,318                           17,019       13,034--21,005   24,778   20,234--29,322
  Age (years)                                                                                                                              
  40--64                                    5,169            4,057--6,280                           20,848       14,671--27,025   26,017   18,728--33,305
  65--74                                    5,761            4,394--7,129                           21,739       10,408--33,071   27,501   14,802--40,199
  75--84                                    10,753           8,495--13,011                          11,443       8,254--14,633    22,196   16,749--27,644
  ≥85                                       9,873            7,404--12,343                          14,249       7,838--20,661    24,123   15,242--33,004
  Sex                                                                                                                                      
  Male                                      7,221            5,741--8,701                           18,681       12,308--25,053   25,901   18,049--33,754
  Female                                    8,287            6,566--10,007                          14,857       11,102--18,612   23,144   17,668--28,619
  Stroke type                                                                                                                              
  Ischaemic                                 7,225            5,750--8700                            17,094       12,632--21,555   24,318   18,381--30,255
  Haemorrhage                               8,230            6,529--9931                            18,315       9,855--26,775    26,545   16,384--36,706

The mean annual cost of unpaid care is £25,897 (95% CI 23,621--28,173) and £15,354 (95% CI 12,501--18,656) in the first and subsequent years after stroke respectively. For lost productivity, respective costs are £1,431 (95% CI 813--2,049) and £1,666 (95% CI 983--2,349); individuals aged 40--64 years (more likely to be of working age) had highest lost productivity costs (£5,172 per stroke case in the first year, £5,895 in subsequent years). [Supplementary Appendices 4](#sup1){ref-type="supplementary-material"}--7 provide further breakdowns for unpaid care and lost productivity.

Combining mean costs for NHS, PSS, unpaid care and lost productivity, the total mean cost of stroke from a societal perspective was £45,409 (42,054--48,763) in the first 12 months after stroke and £24,778 (20,234--29,322) in subsequent years.

Unit cost and length of stay in acute stroke units, probability of repeat stroke and probability of care home admission had a significant impact on costs estimates ([Supplementary Appendix 3](#sup1){ref-type="supplementary-material"}).

Aggregate cost of stroke {#sec11}
------------------------

Aggregate annual costs are estimated at £26 billion (NHS £3.4 billion, 13%; PSS £5.2 billion, 20%; unpaid care £15.8 billion, 61%; lost productivity £1.6 billion, 6%) ([Table 2](#TB2){ref-type="table"}). Costs for prevalent stroke are the main driver of aggregate societal costs due to the much larger number of stroke survivors (950,200) compared to new stroke cases each year (117,600).

###### 

Aggregate cost of incident and prevalent stroke in the UK: base case, low- and high-cost estimates

                                            Mean aggregate cost (£ million, range[^†^](#tblfn1){ref-type="table-fn"}), base case estimates[^‡^](#tblfn2){ref-type="table-fn"}   Mean aggregate cost (£ million, range), low estimates[^‡^](#tblfn2){ref-type="table-fn"}   Mean aggregate cost (£ million, range), high estimates[^‡^](#tblfn2){ref-type="table-fn"}
  ----------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------
  First year cost (incident stroke)                                                                                                                                                                                                                                        
  NHS                                       1,560 (1138,1958)                                                                                                                   1,535 (1120,1927)                                                                          1,585 (1156,1989)
  Formal social care                        565 (412,710)                                                                                                                       521 (380,654)                                                                              610 (445,766)
  Unpaid care                               3,045 (2221,3822)                                                                                                                   2,777 (2026,3486)                                                                          3,313 (2417,4158)
  Lost productivity                         168 (122,211)                                                                                                                       95 (69,120)                                                                                240 (175,302)
  NHS & PSS perspective                     2,126 (1551,2668)                                                                                                                   2,072 (1511,2600)                                                                          2,180 (1590,2736)
  Societal perspective                      5,340 (3896,6702)                                                                                                                   4,945 (3608,6207)                                                                          5,734 (4183,7197)
  Subsequent year cost (prevalent stroke)                                                                                                                                                                                                                                  
  NHS                                       1,844 (1576,2681)                                                                                                                   1,762 (1506,2563)                                                                          1,925 (1645,2799)
  Formal social care                        4,616 (3945,6712)                                                                                                                   4,174 (3567,6069)                                                                          5,058 (4322,7355)
  Unpaid care                               12,783 (10,925,18,588)                                                                                                              10,034 (8575,14,590)                                                                       15,532 (13,275,22,586)
  Lost productivity                         1,387 (1185,2016)                                                                                                                   818 (699,1189)                                                                             1,955 (1671,2843)
  NHS & PSS perspective                     6,460 (5521,9393)                                                                                                                   5,994 (5123,8717)                                                                          6,925 (5918,10,070)
  Societal perspective                      20,630 (17,632,29,999)                                                                                                              16,847 (14,398,24,497)                                                                     24,413 (20,865,35,500)
  Incident and prevalent stroke cost                                                                                                                                                                                                                                       
  NHS                                       3,404 (2714,4639)                                                                                                                   3,298 (2626,4490)                                                                          3,510 (2802,4789)
  Formal social care                        5,181 (4358,7422)                                                                                                                   4,695 (3947,6724)                                                                          5,668 (4768,8121)
  Unpaid care                               15,828 (13,147,24,100)                                                                                                              12,811 (10,602,18,077)                                                                     18,845 (15,692,26,744)
  Lost productivity                         1,555 (1308,2228)                                                                                                                   913 (769,1309)                                                                             2,196 (1847,3146)
  NHS & PSS perspective                     8,586 (7072,12,062)                                                                                                                 8,066 (6635,11,317)                                                                        9,105 (7509,12,807)
  Societal perspective                      25,970 (21,528,26,701)                                                                                                              21,792 (18,006,30,704)                                                                     30,148 (25,049,42,698)

^†^Range based on low- and high-incidence and prevalence estimates.

^‡^Low- and high-cost estimates based on range of mean cost.

Unpaid care dominates forming 57 and 62% of costs of incident and prevalent stroke, respectively. The contribution of PSS costs doubles from 11% in the first year after stroke to 22% in subsequent years, reflecting shifting patterns of post-stroke care over time, i.e. reduced inputs from hospital services and increased dependence on formal and unpaid social care.

Discussion {#sec12}
==========

Interpretation of findings {#sec13}
--------------------------

About, £26 billion represents a substantial cost impact in both formal and unpaid care sectors. Productivity losses were relatively small, but the trial data we drew on indicate that these persist a year after stroke. Of particular note, unpaid carers contribute substantially to stroke care.

Discussion of findings in context of existing evidence {#sec14}
------------------------------------------------------

Our estimates for NHS and social care costs align with those obtained by Xu *et al*. \[[@ref7]\], since we used their model and underlying data for these cost domains. Drawing valid comparisons with other cost-of-illness studies is challenging given inevitable variations in methodology and context. For some context, Smith *et al*. \[[@ref25]\] reported total direct and indirect costs of stroke for Ireland; while their total cost estimates (0.5--0.8 billion Euros as a lower bound estimate at 2007 prices) are lower due to smaller population size, it is nevertheless interesting to note that the proportional contributions to total costs were different. For example, nursing home costs accounted for 44% of total costs, with only 9% attributable to informal care. Wilkins *et al*. \[[@ref26]\] presented total health care costs for cerebrovascular diseases at 2.6 billion Euros per year for the UK (2015 prices) and 3.3 billion Euros for unpaid care and lost productivity. Insufficient details prevent meaningful comparisons, but the overall size of those figures and the proportion that might be attributable to stroke is clearly substantially lower than ours.

Other estimates for aggregate annual costs in the UK are less recent and also generated much lower totals of £7 billion (2004 prices) for England \[[@ref27]\] and £9 billion (2005 prices) for the UK \[[@ref5]\] from similar cost perspectives. Using data now almost a decade older than used here, Saka *et al*. \[[@ref5]\] estimated direct medical care costs as £4.4 billion compared to our estimate of £8.6 billion. More strikingly, they calculated unpaid care at £2.4 billion per year, compared to our £15.8 billion. Such differences may be driven by several factors. For instance, their primary data (the SLSR) represents a specific population and service context, and unpaid care was estimated using different data sources and estimation approaches.

Strengths and limitations {#sec15}
-------------------------

Our data sources are robust but do not reflect substantial recent changes to stroke care. Impacts of these are mixed in nature (e.g. increased short-term treatment costs, reduced length of stay, greater rates of survival), so their overall economic impact remains unclear. All cost-of-illness studies also carry uncertainty in parameter values. Detailed unpaid care and lost productivity data \[[@ref9],[@ref10]\] represent the full economic implications of stroke but may also overestimate costs because longer term costs may be lower than assessed during the trial periods. Until improved precision in underlying data can reduce estimation uncertainty, estimates should be taken as *indicative*, rather than definitive.

Policy recommendations {#sec16}
----------------------

Although significant progress in primary prevention and urgent care has improved stroke incidence and survival, there is scope to achieve more and to reduce costs for both ischaemic and haemorrhagic stroke e.g. through better stroke prevention. Substantial costs of stroke prevalence underline gaps in evidence-based cost-effective rehabilitation interventions \[[@ref28]\], which could improve functioning and quality of life, reduce stroke recurrence and reduce need for longer-term care.

Greater policy support could help extend provision already available and recommended in clinical guidelines, but currently offered at sub-optimal levels risking inequitable variations in care, health and quality of life, and also wasted resources. For example, Xu *et al*. \[[@ref7]\] estimated that each extra person thrombolyzed or receiving early supported discharge services could respectively generate NHS & PSS savings of approximately £6000 or £4000 in just 1 year. Similarly, reduced mortality and length of hospital stay achieved in London through centralizing services to increase delivery of effective urgent care could be replicated elsewhere \[[@ref29],[@ref30]\].

Finally, contributions from unpaid carers reduce pressures on formal services but represent the transfer of significant responsibilities, which can carry negative health, well-being and economic consequences. It is thus important to assess and meet carers' own needs for support \[[@ref31],[@ref32]\].

Conclusion {#sec17}
==========

Inevitably, current resource constraints, system pressures and practical hurdles create challenges for addressing the economic impacts and associated issues. However, it is likely that increased investments and a more co-ordinated approach to care, and research \[[@ref33]\], would go a long way towards containing/reducing future impacts of stroke, improving outcomes and reducing variations in stroke care.

Supplementary Material
======================

###### 

Click here for additional data file.
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